FIND CLINICAL TRIALS

 
 
 

Incyte is developing OX40 agonist antibodies.

OX40 is a member of the tumor necrosis factor (TNF) receptor superfamily that, when activated, may contribute to both adaptive and innate immune responses.

Part of a potent costimulatory pathway, OX40 stimulation results in increased effector T-cell survival, proliferation, and memory, and can lead to enhanced cytotoxic T-cell responses as well as inhibition of regulatory T cells. Stimulation of OX40 may promote immune-mediated antitumor activity.

MOLECULE LIBRARY